A California version of Measure 109 is likely to appear on the 2022 election ballot. Anticipating that such a measure would pass by using the marketing tactics employed in Oregon, eleven start up companies have formed in the last one to two years. Some of these companies have already gone public.
So far no hallucinogenic drugs have been approved by the FDA. We are fortunate though to have faculty at Stanford University and UC researching the uses of hallucinogenic drugs to treat resistant depression, anxiety, drug addiction and PTSD. Researchers like Dr. David E. Olson of UC Davis have even figured out that psychedelic drugs can grow brain neurons.
Dr. Jennifer Dore, an adjunct professor at Stanford University, will speak with us about her work in psychotherapy over the last five years using another psychedelic drug, Ketamine, on January 25, 2022 from 7:00 to 9:00 p.m. She’ll tell us about how effective these drugs really are and what risks they pose to the people who take them.